#United States #Durham #Satsuma Pharmaceuticals #STS101 #ATZUMI

Satsuma Pharmaceuticals Showcases Positive Use of STS101 for Migraine Relief

In a remarkable development for migraine sufferers, Satsuma Pharmaceuticals, Inc. has announced the positive outcomes of its pivotal Phase 3 ASCEND study, exploring the use of STS101 (Dihydroergotamine Nasal Powder, branded as Atzumi™) as a new treatment for acute migraine attacks. This innovative therapeutic option combines Satsuma's proprietary SMART™ delivery technology with a user-friendly nasal device, enhancing patients' experience in managing their condition.

On November 5, 2025, the company revealed findings that bolster the efficacy and patient satisfaction regarding STS101. Notably, results indicated that participants experienced quick relief from migraine pain and other bothersome symptoms, with significant relief achieved as soon as two hours post-administration. Moreover, many patients reported sustained benefits for up to 48 hours after using the drug. This effectiveness positions STS101 as a promising alternative to traditional migraine medications, which often fail to deliver timely results.

Dr. Ryoichi Nagata, President and CEO of Satsuma, expressed pride in the outcomes, emphasizing STS101's potential to serve as a well-tolerated treatment option that can rapidly alleviate symptoms for migraines. Throughout the study, the vast majority of participants stated that STS101 was simple to use, a critical factor for those dealing with acute attacks in challenging situations.

Many participants expressed willingness to choose STS101 over their usual medications due to its faster and more consistent action. This ground-breaking delivery method, therefore, not only targets migraine symptoms effectively but also strives to restore normalcy in the patients' everyday life with minimal disruption.

Renowned neurologist Dr. Jessica Ailani, a certified headache specialist, commented on the importance of the study, underscoring the significance of offering patients reliable, non-oral alternatives. The feedback from the trial also indicates a strong demand for innovative treatments in this area, an objective that STS101 seeks to fulfill.

About the ASCEND Study

The ASCEND study collected data from 482 patients across 54 sites in the U.S., who were diagnosed with migraine with or without aura. Participants had experienced between four to twelve migraine attacks monthly prior to the trial. The results showcased that 446 patients successfully used STS101, representing 10,137 doses administered over the course of the study, thus demonstrating the product's robustness and patient adherence behavior.

Insights on Atzumi™

Atzumi™ is specifically formulated to address the acute treatment of migraines, leveraging the advanced nasal powder formulation of dihydroergotamine alongside an efficient delivery device. This product aims to provide an alternative that is easily portable and user-friendly, critical characteristics desired by those suffering from migraine.

Safety and Usage Considerations

While STS101 holds significant promise, Satsuma Pharmaceuticals emphasizes the importance of adhering to the usage guidelines outlined in the prescribing information. It is crucial for patients to consult with healthcare professionals when considering Atzumi™, especially given warnings regarding the coadministration with strong CYP3A4 inhibitors. Furthermore, those with pre-existing health conditions such as ischemic heart disease or uncontrolled hypertension should proceed with caution.

The results of the ASCEND study shine a light on the potential of STS101 not only to enhance the quality of care offered to migraine sufferers but also to establish a new standard of treatment options. As Satsuma Pharmaceuticals continues to pave the way for innovative therapies, patients can look forward to more accessible and effective solutions for their health needs. For further information or to review the complete study findings, visit the official link.